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QLQ-C30 and QLQ-STO22 were sent to all surviving 
patients without recurrence. The QLQ-C30 scores were 
compared to a Dutch reference population using a one-sam-
ple t test. Spearman’s rank test was used to correlate time 
after surgery to HRQoL, and multivariable linear regression 
was performed to identify factors associated with HRQoL.
Results A total of 222 of 274 (81.0%) patients completed 
the questionnaires. Median follow-up was 29 months (range, 
3–171) and 86.9% of patients had a follow-up >1 year. The 
majority of patients had undergone neoadjuvant treatment 
(64.4%) and total gastrectomy (52.7%). Minimally invasive 
gastrectomy (MIG) was performed in 50% of the patients. 
Compared to the general population, gastrectomy patients 
scored significantly worse on most functional and symptom 
scales (p < 0.001) and slightly worse on global HRQoL (78 
vs. 74, p = 0.012). Time elapsed since surgery did not cor-
relate with global HRQoL (Spearman’s ρ = 0.06, p = 0.384). 
Distal gastrectomy, neoadjuvant treatment, and MIG were 
associated with better HRQoL (p < 0.050).
Conclusion After gastrectomy, patients encounter func-
tional impairments and symptoms, but experience only a 
slightly impaired global HRQoL. Distal gastrectomy, the 
ability to receive neoadjuvant treatment, and MIG may be 
associated with HRQoL benefits.
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Introduction
Gastric cancer is the fifth most common type of cancer 
worldwide [1], and surgical resection is the cornerstone of 
treatment with curative intent. Because survival after gas-
trectomy for cancer has improved since the introduction 
of a more extensive lymphadenectomy and perioperative 
Abstract 
Aim Insight in health-related quality of life (HRQoL) may 
improve clinical decision making and inform patients about 
the long-term effects of gastrectomy. This study aimed to 
evaluate and identify factors associated with HRQoL after 
gastrectomy.
Methods This cross-sectional study used prospective 
databases from seven Dutch centers (2001–2015) including 
patients who underwent gastrectomy for cancer. Between 
July 2015 and November 2016, European Organization for 
Research and Treatment of Cancer HRQoL questionnaires 
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chemotherapy [2, 3], the quality of life following treatment 
has become increasingly important. Various complaints that 
are associated with the treatment, such as a loss of appetite, 
early satiety, reflux, dysphagia, nausea, and change of stools, 
may have a profound impact on patient health-related quality 
of life (HRQoL) [4].
HRQoL is multidimensional, comprising physical, medi-
cal, psychological, and social parameters secondary to a dis-
ease and its treatment, and is considered as one of the most 
important outcome measurements in cancer treatment nowa-
days. Evaluating HRQoL helps health professionals to focus 
on certain aspects to improve current treatment strategies. 
Moreover, understanding HRQoL in patients after surgery 
for gastric cancer is useful for informing patients about the 
(long-term) risks and benefits of an intervention.
High-quality studies evaluating HRQoL after gastrectomy 
for cancer in Western countries are scarce. In addition, it is 
unknown if the HRQoL of patients after gastrectomy dif-
fers from HRQoL in the general population. The aim of this 
multicenter cross-sectional study was therefore to evaluate 
HRQoL in patients who underwent gastrectomy for cancer in 
relationship to the general population and to identify factors 
influencing HRQoL.
Methods
Study design
This cross-sectional multicenter cohort study included data 
from seven referral centers for gastric cancer surgery in the 
Netherlands. All data were extracted from prospectively col-
lected institutional databases. Institutional Review Board 
approval was obtained, and informed consent requirement 
was waived for this study.
Patient population
This study included patients who underwent gastrectomy 
for gastric adenocarcinoma between 2001 and 2015. Only 
patients who were alive and free of disease were approached 
for participation. According to national guidelines, patients 
received either perioperative treatment and gastrectomy or 
gastrectomy alone [5]. Staging was performed in accordance 
with the 7th American Joint Committee on Cancer TNM 
staging system [6, 7]. Information on patient, treatment, and 
histopathological characteristics were collected from the 
prospective institutional databases. Follow-up was updated 
retrospectively.
Quality of life
Cross-sectional HRQoL was measured by means of the 
European Organisation for Research and Treatment of Can-
cer (EORTC) questionnaires. The EORTC-QLQ-C30 was 
developed to assess the HRQoL of patients with cancer in 
general [8]; the EORTC-QLQ-STO22 was developed to 
assess the HRQoL of patients with gastric cancer specifi-
cally [4]. The EORTC-QLQ-C30 and EORTC-QLQ-STO22 
consist of 30 and 22 questions, respectively, scored on a 4- or 
7-point Likert scale, which are translated to a global QoL 
scale, functional scales (physical, role, emotional, cognitive, 
social, and body image), and symptom scales (fatigue, nau-
sea and vomiting, pain, dyspnea, insomnia, appetite loss, 
constipation, diarrhea, financial difficulties, dysphagia, 
reflux, eating restrictions, anxiety, dry mouth, taste, and 
hair loss). Higher scores in global HRQoL and functional 
scales indicate better HRQoL, whereas higher scores in the 
symptom scales indicate more severe symptoms. Patients 
were contacted to complete the questionnaires by mail, 
and received one reminder by telephone in the case of no 
response.
Statistical analyses
HRQoL data obtained by the questionnaires were scored 
according to the manual [9]. The patients’ HRQoL scores 
of the EORTC-QLQ-C30 were compared to a general Dutch 
reference population consisting of 1731 individuals by per-
forming one-sample t tests [10]. Subgroup analyses were 
performed on age and gender, and of patients who had a 
follow-up ≥12 months. Based on previous studies, a differ-
ence in HRQoL >10 points was considered clinically rel-
evant [11]. A Spearman’s rank correlation coefficient (ρ) was 
calculated to measure the dependence of different HRQoL 
scores to time since surgery. A positive or negative correla-
tion coefficient was considered very strong if ρ > 0.8, strong 
if ρ = 0.6–0.8, moderate if ρ = 0.4–0.6, weak if ρ = 0.2–0.4, 
and very weak if ρ < 0.2. Finally, multivariable linear regres-
sion analysis with stepwise backward elimination was per-
formed to evaluate the association between HRQoL scales 
and patient, surgical, and histopathological variables. These 
variables were chosen based on their possible association 
with HRQoL as demonstrated by previous studies [12–16]. 
Major complications were defined as complications requir-
ing a re-intervention or intensive care admission. A p value 
< 0.05 was considered statistically significant. All statistical 
analyses were performed using IBM SPSS version 21.
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Results
Patients
A total of 683 patients who underwent gastrectomy for 
gastric adenocarcinoma were identified from the combined 
database. Some 409 patients were excluded because of 
death or recurrent disease. The remaining 274 patients were 
invited to participate in the study and were sent HRQoL 
questionnaires. The questionnaires were completed by 222 
of 274 (81.0%) patients (Supplementary file 1).
Baseline
There were no differences in patient and tumor charac-
teristics, nor in postoperative outcomes, of respondents 
(n = 222) and non-respondents (n = 52). The median fol-
low-up at completing the questionnaires was 29 months 
(range, 3–171); 193 (86.9%) of the respondents had a 
follow-up >1 year, whereas 40 (18.0%) had a follow-up 
>5 years (Fig. 1). Patient, surgical, and histopathological 
characteristics of the patients are shown in Table 1. Some 
143 (64.4%) patients had undergone neoadjuvant treatment, 
117 patients (52.7%) a total gastrectomy, and 111 patients 
(50.0%) a minimally invasive gastrectomy (MIG). Of the 
patients receiving perioperative treatment, most received 
perioperative chemotherapy according to a regimen similar 
to epirubicin, cisplatin, and capecitabin [3]. Radiotherapy 
was not routinely performed, except for some patients who 
received adjuvant chemoradiation as part of the CRITICS 
trial [17]. The majority of patients (n = 119, 53.6%) had an 
advanced tumor stage (≥II). Major postoperative complica-
tions were seen in 42 (18.9%) patients. Median hospital stay 
was 9 days (range, 3–124), and 24 (10.8%) patients were 
readmitted within 30 days after discharge.
HRQoL versus reference population
The mean HRQoL score and standard deviation of the 
study population and the reference population are shown 
in Table 2 [10]. Patients who underwent gastrectomy for 
cancer had statistically significantly lower scores than the 
reference population for all functional scales (p < 0.001) and 
most general symptom scales (p < 0.002), expect for pain 
symptoms (p = 0.067) (Table 2). This difference was clini-
cally relevant for most scales (physical, role, cognitive, and 
social functioning; fatigue, nausea, and vomiting, dyspnea, 
appetite loss, diarrhea, and financial difficulties). On global 
HRQoL, patients scored significantly worse compared to the 
reference population, although this difference was clinically 
irrelevant (weight mean difference = 4, p = 0.002). The dis-
tribution of global HRQoL scores is shown in Fig. 2: 78% 
of patients scored a global HRQoL >60, compared to 83% 
in the reference population (p = 0.027). 
In a subgroup analysis of men or women compared to a 
reference population of comparable age (60–69 years), simi-
lar results (as demonstrated in Table 2) were found (Sup-
plementary files 2 and 3). In addition, subgroup analyses of 
patients with a follow-up ≥12 months also did not influence 
the results (Supplementary file 4).
HRQoL and time elapsed since surgery
Spearman rank correlation coefficients between HRQoL and 
time after surgery were calculated, demonstrating weak cor-
relations ranging from −0.13 to +0.13 (Table 3). In patients 
with follow-up <1 year, a larger variation of correlations 
was present, ranging from −0.46 to +0.29. Moreover, there 
was no difference in HRQoL between the years of surgery 
(p = 0.523).
Fig. 1  Timing of quality of life 
(QoL) questionnaire (months 
after surgery)
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Predictive factors for HRQoL
Global HRQoL was significantly higher in patients who 
underwent distal gastrectomy [+6.5, 95% CI (0.8;12), 
p  =  0.026] and neoadjuvant treatment [+8.2, 95% CI 
(1.8;15), p = 0.012]. Moreover, both distal gastrectomy 
and neoadjuvant treatment were associated with better 
Table 1  Baseline characteristics of 222 patients who underwent gas-
trectomy for cancer
Factor n = 222 (%)
Age (years) [mean (± SD)] 67.7 (± 10.6)
BMI (kg/m2) [mean (± SD)] 25.5 (± 4.4)
Gender
 Male 141 (63.5)
 Female 81 (36.5)
Malignancy history
 No 157 (86.3)
 Yes 25 (14.7)
 Unknown 40
Comorbidity 169 (76.1)
 Cardiovascular 110 (49.5)
 Pulmonary 37 (16.7)
 Diabetes mellitus 37 (16.7)
ASA
 I 33 (14.9)
 II 141 (63.5)
 III 46 (20.7)
 IV 2 (0.9)
Neoadjuvant treatment 143 (64.4)
Adjuvant treatment 67 (30.2)
Year of surgery
 2001–2004 3 (11.4)
 2005–2009 10 (4.5)
 2010–2012 66 (29.7)
 2013–2015 143 (64.4)
Surgical type
 Distal gastrectomy 105 (47.3)
 Total gastrectomy 117 (52.7)
Surgical approach
 Open 111 (50.0)
 Laparoscopic 111 (50.0)
Complications 89 (40.1)
 Major 42 (18.9)
 Anastomotic leakage 16 (7.2)
 Pulmonary 24 (10.8)
Hospital stay (median, range) (days) 9 (3–124)
Radicality
 R0 214 (96.4)
 R+ 5 (2.3)
 Missing 3 (1.4)
pTNM stage
 0 15 (6.8)
 I 88 (39.6)
 II 78 (35.1)
 III 40 (18.0)
 IV 1 (0.5)
Table 2  Mean (standard deviations) health-related quality of life 
(HRQoL) scores of 222 patients who underwent gastrectomy for can-
cer compared to the general Dutch population
Scores are presented as mean [± SD]
a Score range 0–100: higher scores represent a better quality of life or 
level of functioning
b Score range 0–100: higher scores represent more severe symptoms
Bold values indicate significant variables (p < 0.05)
Total n = 222 Reference 
population 
n = 1731
WMD p value
Quality of life questionnaire (QLQ)-C30
 Global quality of 
 lifea
74 [21] 78 [17] −4 0.002
Functional  scalesa
 Physical 79 [20] 90 [15] −11 <0.001
 Role 73 [29] 89 [21] −16 <0.001
 Emotional 81 [24] 89 [16] −8 <0.001
 Cognitive 81 [22] 92 [15] −11 <0.001
 Social 81 [26] 94 [16] −13 <0.001
General symptom  scalesb
 Fatigue 33 [27] 17 [20] +16 <0.001
 Nausea and 
vomiting
14 [22] 2.7 [10] +11 <0.001
 Pain 18 [26] 15 [22] +3 0.067
 Dyspnoea 18 [25] 7.1 [17] +11 <0.001
 Insomnia 20 [29] 14 [23] +6 0.002
 Appetite loss 21 [32] 3.3 [12] +18 <0.001
 Constipation 10 [22] 4.8 [14] +5 0.001
 Diarrhea 18 [26] 3.9 [14] +14 <0.001
 Financial dif-
ficulties
16 [29] 3.1 [13] +13 <0.001
QLQ-STO22
Functional  scalesa
 Body image 82 [28] NA NA
General symptom  scalesb
 Dysphagia 16 [21] NA NA
 Pain 20 [22] NA NA
 Reflux 22 [25] NA NA
 Eating restric-
tions
25 [25] NA NA
 Anxiety 30 [27] NA NA
 Dry mouth 21 [30] NA NA
 Taste 17 [29] NA NA
 Hair loss 18 [32] NA NA
Factors influencing health-related quality of life after gastrectomy for cancer 
1 3
HRQoL scores in other symptom and functioning scales 
(Table 4). Minimally invasive surgery resulted in signifi-
cantly better HRQoL scores on physical functioning [+7.5 
(2.4;12), p = 0.004], fatigue [−7.0 (−14;−0.05), p = 0.048], 
pain [−9.1 (−16;−2.6), p = 0.007], and dry mouth [−9.5 
(−17;−1.8), p = 0.015]. Furthermore, female gender and a 
high ASA score were predictive factors for impaired HRQoL 
in some scales.
Discussion
This cross-sectional multicenter study demonstrates that 
patients who underwent gastrectomy experienced func-
tional complaints and symptoms, whereas global HRQoL 
was only slightly lower compared to the Dutch reference 
population. Most importantly, distal gastrectomy and the 
ability to receive neoadjuvant treatment were associated with 
higher global HRQoL, whereas minimally invasive surgery 
was associated with better functional and symptom scores.
The results of this study are relevant, as they may rep-
resent the average population undergoing gastrectomy for 
cancer in the West. Unfortunately, to date, most studies on 
HRQoL after gastrectomy lacked data on patient character-
istics [12], were performed in the Asian population [13–15], 
or selected patients by age [14], minimally invasive proce-
dures [13, 14], comorbidities [13, 14], tumor stage [15], or 
perioperative chemotherapy [16]. The present study is the 
first study to include all disease-free patients who underwent 
gastrectomy for cancer and to compare the results to a gen-
eral Western reference population.
This study demonstrated that the absolute difference in 
global HRQoL compared to the general population is clini-
cally irrelevant. These findings correspond with previous 
studies on HRQoL after other types of cancer surgery, such 
as esophagectomy [18] and breast cancer surgery [19], and 
demonstrate that patients can achieve a high life satisfac-
tion after surviving cancer, regardless of the presence of 
Fig. 2  Distribution of global 
HRQOL-scores (EORTC-
QLQ-C30) of 222 patients who 
underwent gastrectomy for 
cancer compared to the general 
Dutch population
Table 3  Spearman’s rank correlation coefficients between quality of 
life and length of follow-up (FU) since surgery
FU follow-up
Bold values indicate significant variables (p < 0.05)
Spearman’s rank coefficient (ρ)
Total cohort 
(n = 222)
Follow-up 
<1 year 
(n = 29)
Follow-up 
>1 year 
(n = 193)
Quality of life questionnaire (QLQ)-C30
 Global quality of  lifea + 0.06 − 0.01 + 0.11
Functional  scalesa
 Physical − 0.08 − 0.11 − 0.03
 Role − 0.02 − 0.17 + 0.06
 Emotional + 0.07 − 0.11 + 0.14
 Cognitive + 0.08 + 0.10 + 0.20
 Social + 0.03 − 0.03 + 0.07
General symptom  scalesb
 Fatigue + 0.08 + 0.29 − 0.01
 Nausea and vomiting + 0.07 − 0.14 + 0.06
 Pain + 0.06 + 0.03 − 0.01
 Dyspnea + 0.03 + 0.17 − 0.03
 Insomnia + 0.04 − 0.11 − 0.05
 Appetite loss − 0.02 − 0.25 − 0.05
 Constipation − 0.07 − 0.17 − 0.08
 Diarrhea + 0.07 − 0.06 + 0.09
 Financial difficulties − 0.02 − 0.14 − 0.06
QLQ-STO22
Functional  scalesa
 Body image + 0.03 + 0.25 + 0.02
General symptom  scalesb
 Dysphagia − 0.03 − 0.32 − 0.03
 Pain − 0.02 − 0.16 − 0.09
 Reflux + 0.13 + 0.01 + 0.13
 Eating restrictions − 0.11 − 0.11 − 0.07
 Anxiety − 0.11 − 0.03 − 0.13
 Dry mouth + 0.02 − 0.03 + 0.03
 Taste − 0.13 + 0.05 − 0.13
 Hair loss − 0.05 − 0.46 − 0.03
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symptoms or functional impairment. This adjustment might 
be explained by a phenomenon called reconceptualization, 
which is well known in HRQoL assessments [20]. Recon-
ceptualization implies that certain circumstances, such as 
surviving cancer, can alter the internal reference points of an 
individual’s well-being that are critical for an evaluation of 
HRQoL. As a result, objective impairments in different areas 
of life can be measured, but the overall HRQoL is based on 
other factors and can therefore be compared to data before 
the circumstance or from the general population [14].
HRQoL benefits of minimally invasive gastrectomy over 
open gastrectomy were also demonstrated by an Asian ran-
domized controlled trial [15]. Comparable benefits were 
found on physical functioning and symptoms. However, ben-
efits in global HRQoL could not be confirmed by the present 
study. This difference could be explained because the present 
study evaluated a population with longer follow-up, whereas 
one might expect global HRQoL benefits of minimally inva-
sive surgery mainly in the short term. Although minimally 
invasive gastrectomy may have additional advantages over 
open gastrectomy [21–25], results from more randomized 
controlled trials are awaited [26–28].
Other factors possibly influencing HRQoL identified in 
this study were the extent of gastrectomy, neoadjuvant treat-
ment, gender, and time since surgery. During distal gastrec-
tomy, a functional part of the stomach is preserved and a less 
extensive lymphadenectomy is required [29], contributing 
to a higher HRQoL compared to total gastrectomy on sev-
eral domains [13, 30]. An interesting finding is the higher 
HRQoL in patients who were able to receive neoadjuvant 
treatment, compared to patients who did not receive neoad-
juvant treatment. Although chemotherapy has been shown 
to increase HRQoL in the palliative setting [31], the only 
evidence available in the curative setting demonstrates that 
physical fitness of patients decreases during neoadjuvant 
treatment [32]. The lower HRQoL after gastrectomy found 
in women is consistent with previous studies and the general 
reference population [10, 18]. Elapsed time since surgery 
did not correlate with HRQoL, which may be a result of 
the long-term follow-up of patients in this study. Previous 
studies have demonstrated that time since surgery is mainly 
associated with HRQoL in the early recovery period [16], 
whereas QoL remains relatively stable after the first year 
following surgery [33].
There are some limitations of this study that need to 
be addressed. First, although subgroup analyses of males 
and females of comparable age were performed, we can-
not exclude confounding caused by differences between the 
study population and general population in baseline. Sec-
ond, because patients with undiagnosed recurrent disease 
might have been included, this factor could have decreased 
the HRQoL measured in the study population [16]. Third, 
despite correcting for confounding factors, selection bias Sc
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cannot be fully excluded. For instance, selection bias might 
explain the higher HRQoL in patients who received neo-
adjuvant treatment. Another form of selection bias might 
be caused by the inclusion of mainly long-term survivors, 
which may have led to an overestimation of the quality of 
life of patients following gastrectomy in this study. Last, the 
cross-sectional design of this study did not allow the analysis 
of repeated measurements of HRQoL over time.
In conclusion, although surviving patients experience 
significant symptoms and functional problems after gas-
trectomy, global HRQoL is more or less comparable to the 
general population. Distal gastrectomy, the ability to receive 
neoadjuvant treatment, and minimally invasive surgery 
could be associated with HRQoL benefits and may therefore 
be preferred. The results of this study may help healthcare 
professionals during clinical decision making and the pre-
operative process of informed consent.
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